Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation.
Pharmaceuticals are not permitted on to the market unless they are granted regulatory approval. The regulatory process is, therefore, crucial in whether or not a drug is widely prescribed. Regulatory agencies have developed standards of performance that pharmaceuticals are supposed to meet before entering the market. Regulation of technologies is often discussed by reference to the precautionary principle. In contrast, this paper develops the concept of the 'permissive principle' as a way of understanding the departure of regulators' practices from standards of drug efficacy to which regulatory agencies themselves subscribe. By taking a case study of antidepressant regulation in the UK and the USA, the mechanisms of permissive regulatory practices are examined. An STS methodology of both spatial (international) and temporal comparisons of regulatory practices with regulatory standards is employed to identify the nature and extent of the permissive regulation. It is found that the permissive principle was adopted by drug regulators in the UK and the USA, but more so by the former than the latter. Evidently, permissive regulation, which favours the commercial interests of the drug manufacturer, but is contrary to the interests of patients, may penetrate to the heart of regulatory science. On the other hand, permissive regulation of specific drugs should not be regarded as an inevitable result of marketing strategies and concomitant networks deployed by powerful pharmaceutical companies, because the extent of permissive regulation may vary according to the intra-institutional normative commitments of regulators to uphold their technical standards against the commercial interests of the manufacturer. Likely sociological factors that can account for such permissive regulatory practices are 'corporate bias', secrecy and excessive regulatory trust in the pharmaceutical industry in the UK, political expediency and ideological capture in the USA, combined in both countries with some regulatory deference to the clinical autonomy of the psychiatry profession.
Abraham
John
J
Department of Sociology, Centre for Research in Health and Medicine, University of Sussex, Falmer, Brighton, UK. J.W.Abraham@sussex.ac.uk
Davis
Courtney
C
D000928:Antidepressive Agents / Q000266:history*; D002986:Clinical Trials as Topic / Q000266:history; D003863:Depression / Q000188:drug therapy / Q000266:history; D017277:Drug Approval / Q000266:history; D004341:Drug Evaluation / Q000266:history*; D004335:Drug and Narcotic Control / Q000266:history*; D049673:History, 20th Century; D006801:Humans; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration / Q000266:history
D000928:Antidepressive Agents